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Available online 31 December 2015Differentiated cells retain the genetic information of the donor but the extent to which phenotypic differences
between donors or batches of differentiated cells are explained by variation introduced during the differentiation
process is not fully understood. In this study, we evaluated four separate batches of commercially available
neurons originating from the same iPSCs to investigate whether the differentiation process used in manufactur-
ing iPSCs to neurons affected genome-wide gene expression and modiﬁed cytosines, or neuronal sensitivity to
drugs. No signiﬁcant changes in gene expression, as measured by RNA-Seq, or cytosine modiﬁcation levels, as
measured by the Illumina 450K arrays, were observed between batches relative to changes over time. As expect-
ed, neurotoxic chemotherapeutics affected neuronal outgrowth, but no inter-batch differences were observed in
sensitivity to paclitaxel, vincristine and cisplatin. As a testament to the utility of the model for studies of neurop-
athy, we observed that genes involved in neuropathy had relatively higher expression levels in these samples
across different time points. Our results suggest that the process used to differentiate iPSCs into neurons is
consistent, resulting in minimal intra-individual variability across batches. Therefore, this model is reasonable
for studies of human neuropathy, druggable targets to prevent neuropathy, and other neurological diseases.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Chemotherapy1. Introduction
Neurodegenerative diseases and neuropathy are difﬁcult to study
due to lack of relevant humanmodels (Phillips et al., 2009). Cell culture
systems and primary rodent cultures have proven to be indispensable to
clarify disease mechanisms and provide insights into gene functions.
However, the current models have not provided much in terms of
therapy for inherited neuropathies (known collectively as Charcot–
Marie-Tooth disease) (Ekins et al., 2015), and the only effective
treatments for diabetic neuropathy are glucose control and pain man-
agement (Callaghan et al., 2012). Chemotherapy-induced peripheral
neuropathy (CIPN) is a common neurotoxicity affecting 20–40% of pa-
tients receiving chemotherapy (Smith et al., 2013). To truly understand
and ﬁnd relevant druggable targets that are causative, a cellular model
that represents neuropathy is essential.
With recent advances in stem cell technology, the ability to differen-
tiate human induced pluripotent stem cells (iPSCs) to neurons provides, Suite 1400, Chicago, IL, 60611,
D 7100, University of Chicago,
Zhang),
. This is an open access article underus with a new and potentially relevant human neuronal model. In
addition, iPSC-differentiated neurons can be created fromdiseased indi-
viduals or individuals with severe sensitivity to neurotoxic chemother-
apy to provide a model that will allow for the identiﬁcation of in vitro
phenotypic characteristics relevant to the disease or sensitivity to neu-
rotoxic drug. These neurons may yield targets essential to overcoming
and preventing symptoms associated with heritable neuropathy or
CIPN. Stem cell technology has revolutionized the ﬁeld of “in vitro
disease modeling” (Sandoe and Eggan, 2013), as evidenced by the ﬁrst
set of drugs emerging into clinical trials from the use of iPSC derived
neurons from patients with neurological diseases (Mullard, 2015).
Human ﬁbroblasts were reprogrammed from an individual into no-
ciceptor neurons without creation of iPSCs and the neurons exhibited
sensitization to the chemotherapeutic drug oxaliplatin,modeling the in-
herent mechanisms underlying painful CIPN (Wainger et al., 2015);
however, the advantage to creating iPSCs as an intermediate is that
they can grow indeﬁnitely, thus providing a ready source to create addi-
tional neurons of the same genetic background. Recently, our laboratory
developed a potential model to evaluate CIPN by employing commer-
cially available human neurons differentiated from iPSCs (Wheeler
et al., 2015). We found reproducible differences in morphological
characteristics including neurite outgrowth phenotypes, cellular viabil-
ity and apoptosis following treatment with four distinct chemothera-
peutic drugs: vincristine, paclitaxel, cisplatin and hydroxyurea. Thisthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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knockdown on neuronal sensitivity to chemotherapeutics of genes
identiﬁed through clinical genome-wide association studies (GWAS)
of CIPN (Wheeler et al., 2015; Leandro-Garcia et al., 2012; Diouf et al.,
2015; Komatsu et al., 2015).
The potential of using the human iPSC-derived neuron model for
larger genetic association studies requires an understanding of hetero-
geneity of cultures and to partition the variance associated with iPSC
reprograming, culturing, and differentiation (Boulting et al., 2011;
Rouhani et al., 2014; Thomas et al., 2015). A major concern in the ﬁeld
of stem cell technology is that techniques to reprogram cells could
introduce variation that masks important genetic differences between
individuals. A recent study demonstrated that the genetic background
of iPSCs generated from peripheral blood mononuclear cells or ﬁbro-
blasts accounted for more of the variation in gene expression between
iPSC lines than any other tested factors such as cell type of origin or
reprogramming method (Rouhani et al., 2014). These studies suggest
that future studies should focus on collecting a large number of donors
rather than generating large numbers of lines from the same donor.
Since industrial grade cells can now be made, the evaluation of
epigenetics, gene expression and phenotypic variation from batch to
batch is an important consideration.
In this study, we obtained multiple batches of iCell® Neurons
(iPSC-derived human cortical neurons) differentiated from a single
iPSC originating from ﬁbroblasts of an individual to evaluate inter-
batch differences in gene expression, cytosine modiﬁcation levels,
and pharmacologic response to chemotherapeutics. To determine
the utility of these cells for studies of neuropathy and other
neurological diseases, we evaluated genes involved in hereditary
neuropathy at different time points in culture as neurites were
formed. We showed a consistent enrichment of genes with relatively
higher expression levels among hereditary neuropathy associated
genes over time.
2. Methods
2.1. ICell Neurons
Neurons (iCell Neurons®) were purchased from Cellular Dynamics
International (CDI, Madison, WI, USA). iCell Neurons are an ~98% pure
(Tuj1+/Nestin−) pan-neuronal population of GABAergic and to a
lesser degree glutamatergic neurons produced from human induced
pluripotent stem cells. All batches of iCell Neurons are tested for
sterility, viability, purity and morphology, and released according to
strict manufacturer's standards. Four batches of iCell Neurons (batch
numbers: 1366431, 1366825, 1369525, 1362632) were thawed and
maintained according to the manufacturer's protocol. Each batch of
iCell Neurons was mixed with 3.3 μg/ml laminin (Sigma-Aldrich) prior
to seeding on poly-D-lysine coated 96-well Greiner Bio-One plates at a
density of 1.33 × 104 cells/well. Approximately 1.1 × 106 neuron cells
were pelleted immediately for the 0 h sample by spinning at 300 ×g
for 10 min and either lysed using Quizol (Qiagen) for RNA extraction
or media removed from pellet before storing both samples at−20 °C.
For the cell collections to evaluate modiﬁed cytosine and gene expres-
sion, cells were pelleted at 0, 4, 28, and 76 h and then extracted DNA
and RNA.
2.2. Drug preparation and treatment
Paclitaxel (Sigma-Aldrich) was prepared in the semi-dark by dis-
solving powder in 100% DMSO and ﬁltered to obtain a stock solution
of 58.4 mM. Control wells were treated with 0.17% ﬁnal concentration
of DMSO to match drug treatments. Cisplatin (Sigma-Aldrich) was pre-
pared in the semi-dark by dissolving powder in 100%DMSO and ﬁltered
to obtain a stock solution of 20 mM. Control wells were treated with
0.2% ﬁnal concentration of DMSO to match drug treatment. Vincristine(Sigma-Aldrich) was prepared on ice in the dark by dissolving powder
in cold PBS and ﬁltered to obtain a stock solution of 100mM. Vincristine
stocks were each diluted independently then added into the media and
onto the cells before proceeding to the next dilution. All stock drugs
were serially diluted in media for ﬁnal dosing concentrations ranging
from 0.01 μM to 100 μM, increasing by factors of ten. Cells were plated
and 4 h later treated with increasing concentrations of drug for 72 h.
2.3. High content imaging and neurite outgrowth analysis
After drug treatments of 72 h, neurons were stained for 15 min at
37 °C with 1 μg/ml Hoechst 33342 (Sigma-Aldrich) and 2 μg/ml Calcein
AM (Molecular Probes, Life Technologies Inc., Carlsbad, CA, USA) then
washed twice using dPBS without calcium or magnesium
(LifeTechnologies). Imaging was performed at 10× magniﬁcation
using an ImageXpress Micro (Molecular Devices, LLC, Sunnyvale, CA,
USA) at the University of Chicago Cellular Screening Core. Individual
cell measurements of total neurite outgrowth (sum of the length of all
processes), number of processes and number of brancheswere calculat-
ed using theMetaXpress software Neurite Outgrowth ApplicationMod-
ule (Molecular Devices, LLC). At least 500 cells per dosewere quantiﬁed
in triplicate for three independent experiments.
2.4. Nucleic acid isolation
At each time point, DNA was extracted by adding 50 μl per well of
tissue digestion buffer (100 mM NaCl, 50 mM Tris 8.0, 100 mM EDTA,
1% SDS) along with 2 mg/ml Proteinase K (Denville Scientiﬁc; South
Plainﬁeld, NJ, USA). The plate was sealed with paraﬁlm and agitated
overnight at 55 °C using 200 RPM in an Innova orbital shaker
(Eppendorf; Enﬁeld, CT). The digested cells from each well were com-
bined and DNA extracted with equal volume of phenol: chloroform
(Invitrogen), vortexing for 10 min (Lab Vortex-setting of 4) and the
samples were centrifuged for 5 min at 14,000 ×g. The aqueous phase
was collected, extracted with equal volume of chloroform and repeated
two times. The DNA was precipitated with equal volume 100% ethanol
and centrifuged for 10min at 14,000 ×g. Two washes with 70% ethanol
produced a pellet thatwas air dried for 10min at room temperature and
ﬁnally dissolved in 50 μl of 10 mM Tris (pH 8.0) for 3 days at 4 °C then
stored at−80 °C.
RNA isolationwas performed after removal of media and addition of
50 μl Qiazol per well plate for 5 min at room temperature to lyse cells.
After vigorously pipetting each well several times, each batch was col-
lected and stored for further processing at−80 °C. When all the time
points had been collected, the RNA was puriﬁed using the Ambion
RNA protocol (15596026.PPS), substituting Qiazol as the lysing reagent
after consulting with the company. The ﬁnal pellet was resuspended in
50 μl of RNase-free water, dissolved at 55 °C for 10 min, aliquoted, and
stored at−80 °C.
Nucleic acid quantiﬁcation was performed using the Quibit dye for
RNA or dsDNA kits (Molecular Probes, Life Technologies), as per the
manufacturer's speciﬁcations.
2.5. RNA-Seq and analysis
1 μg RNA from each time point was submitted to the University of
Chicago Genomics Core. RNA quality was then checked on the Agilent
Bio-analyzer 2100. RNA-Seq libraries were generated in the core using
Illumina RS-122-2101 TruSeq® Stranded mRNA LT libraries and the
ﬁnal libraries checked again on the Agilent bio-analyzer 2100, which
was followed by sequencing on the Illumina HiSeq2500. High quality
sequencing paired-end reads of 100 bp in each (76.4 to ~83.7%) were
mapped to the human genome reference (hg19) using TopHat2 (Kim
et al., 2013). Estimated genome coverage is 33.6% to ~52.1%. Cufﬂinks
(Trapnell et al., 2010)were then used to quantify gene expression levels
of the assembled transcripts. Fragments per kilobase of transcript per
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with FPKM larger than one remained for downstream analysis. The
raw RNA-Seq reads have been deposited to the NIH Short Read Archive
(accession no. SRP056287).
2.6. 450K array proﬁling and analysis
1 μg puriﬁed DNA from each time point was submitted to the Uni-
versity of Chicago Genomics Core where it was converted with the EZ-
96 DNAMethylation™ Kit, as per the manufacturer's protocol, followed
by array analysis using the Illumina Inﬁnium HumanMethylation450
BeadChip (450K array) Kit, which interrogates N480,000 CpG sites in
the human genome. The β-value (proportion of modiﬁed signals)
values were quantile-normalized across all samples. CpGs probes that
failed 450K proﬁling (detection P N 0.01) in N5% samples were removed
from consideration. Themanufacturer's annotations for CpGs sites were
checked by aligning CpG probes to the human genome reference (hg19)
following our previous publication (Moen et al., 2013). The raw 450K
array data have been deposited into the NIH Gene Expression Omnibus
database (accession no. GSE66330).
2.7. Batch effect evaluation
Since the conventional principal component analysis (PCA) is not
effective for identifying batch effects if they are not the largest source
of variation, we applied the gPCA method (Reese et al., 2013) to deter-
mine whether there was a batch effect observed in the RNA-Seq data
andmethylation data. Brieﬂy gPCA guides the singular-value decompo-
sition to look for batch effects in the data based on the batch indicator
matrix. A statistic δ was derived from the ratio of the variance of the
ﬁrst PC from gPCA to the variance of the ﬁrst PC from unguided PCA. A
larger δ is expected if there exists a batch effect. To determine the signif-
icance, an empirical P-value was estimated by permuting the batch vec-
tor 1000 times. The percentage of total variance explained by batchwas
then calculated as a percentage of variance proportion increase of the
ﬁrst PC using guided PCA. In addition, for each gene, we performed a
two-way ANOVA test to test the batch effect. False discovery rate
(FDR) was estimated using the Benjamini–Hochberg procedure
(Benjamini, 1995).
2.8. Evaluation of enrichment of neuropathy-associated genes
Hereditary neuropathy- (48 genes) and diabetes- (27 genes) associ-
ated gene lists were downloaded from OnlineMendelian Inheritance in
Man (OMIM) (accessed on Oct. 30, 2014). In addition, 13 CIPN associat-
ed genes were extracted from previous publications (Leandro-Garcia
et al., 2012; Seretny et al., 2014; Wheeler et al., 2013; Baldwin et al.,
2012; Leandro-Garcia et al., 2013; Li et al., 2014, 2015a; Beutler et al.,
2014; Li et al., 2015b; Boora et al., 2015) (Table 1). We further obtained
a list of additional neuropathy-associated genes from Reyes-Gibby et al.Table 1
Published CIPN associated genes.
HGNC symbol Cytogenetic band Description
CX3CL1 16q21 Chemokine (C-X3-C motif) ligand 1
EPHA4 2q36.1 Ephrin receptor A4
EPHA5 4q13.2 Ephrin receptor A5
EPHA6 3q11.2 Ephrin receptor A6
FGD4 12p11.21 FYVE, RhoGEF and PH domain containin
FZD3 8p21.1 Frizzled class receptor 3
LIMK2 22q12.2 LIM domain kinase 2
PRX 19q13.2 Periaxin
RFX2 19p13.3 Regulatory factor X, 2 (inﬂuences HLA c
TLR4 9q33.1 Toll-like receptor 4
TUBB2A 6p25.2 Tubulin, beta 2A class IIa
XKR4 8q12.1 XK, Kell blood group complex subunit-r
ARHGEF10 8p23.3 Rho guanine nucleotide exchange facto(Reyes-Gibby et al., 2015). We calculated the median gene expression
levels of neuropathy-associated genes (hereditary neuropathy or CIPN,
separately) at each time point. To determine the null distribution ofme-
dian gene expression, we randomly sampled the same number of genes
across whole transcriptome according to the RefSeq annotations (Pruitt
et al., 2005). Empirical P-values of enrichment were calculated as the
probability of getting at least the median expression value as
neuropathy-associated genes under the null distribution. We per-
formed the same analysis with diabetes-associated genes.
3. Results
3.1. Scheme of iPSC differentiation efﬁciency analysis in cortical neurons
To investigate whether the differentiation process from iPSC to neu-
rons introduces variation in epigenetics and gene expression, we evalu-
ated these parameters in four distinct batches of neurons created from a
single iPSC clone from a single individual (Fig. 1, Table 2). iPSC-
differentiated cortical neurons are a mixed population of neuronal
cells consisting mainly of GABAergic and glutamatergic neurons
(Wheeler et al., 2015). These differentiated neurons were shown to be
Tuj1 positive with no obvious morphological differences between
three neuronal batches imaged at 48 and 72 h after plating (Fig. 1).
We evaluated batch effect between lots by analyzing gene expression
using RNA-Seq and modiﬁed cytosines using the Illumina 450K arrays,
as well as temporal changes of these measurements following neuronal
plating. These neurons quickly assumed a typical neuronal morphology
with branching neurites that can bemeasured using an imaging system.
3.2. Transcriptomic proﬁling of different batches of neurons
All four batches of cortical neurons differentiated from iPSCs were
analyzed using RNA-Seq at 0, 4, 28 and76h followingplating. Tradition-
al PCA of the log-transformed FPKM matrix was ﬁrst plotted for
visualization (Fig. 2A). gPCA was then performed to derive statistical
conclusions. Permutation test showed that there was no signiﬁcant
batch effect detected among RNA-Seq measurements (δ = 0.49;
P-value = 0.93). Of the total variances in gene expression among sam-
ples, which is represented by summations of squared deviation from
mean value, 71.55% could be explained by temporal changes, while
27.05% of the total variance could be explained by different batches
(see details in theMethods section). Therefore, the temporal effect con-
tributes predominantly to the observed variances. The sum of variances
derived from these twomajor sources of variationmay not be equal to 1
due to their possible interaction. Notably, two protein-coding genes
(DNASE2B encoding deoxyribonuclease II beta and PALMD encoding
palmdelphin) were found to be signiﬁcant for the batch effect at a le-
nient cutoff of 20% FDR, with no detection of functional enrichment
among batch effect genes. Furthermore, none of the neuropathy-
associated genes (Leandro-Garcia et al., 2012; Wheeler et al., 2013;References
Li et al. (2015a)
Leandro-Garcia et al. (2013)
Baldwin et al. (2012), Leandro-Garcia et al. (2013)
Leandro-Garcia et al. (2013)
g 4 Baldwin et al. (2012)
Reyes-Gibby et al. (2015)
Leandro-Garcia et al. (2013)
Beutler et al. (2014)
lass II expression) Wheeler et al. (2013)
Li et al. (2014, 2015b)
Leandro-Garcia et al. (2012)
elated family, member 4 Baldwin et al. (2012), Leandro-Garcia et al. (2013)
r 10 Beutler et al. (2014), Boora et al. (2015)
Fig. 1. Overall schematic to investigate epigenetic and gene expression differences between batches and following time in culture. Four independent batches of neurons reprogrammed
from a single iPSC from a single humanﬁbroblastswere purchased fromCellular Dynamics, Int. These three neuron batches (shown) aswell as a fourth batch (not shown)were pelleted to
evaluate genome wide gene expression (RNA-Seq) and modiﬁed cytosines (Illumina 450K). In the phenotypic assay, three neuron batches out of the four were plated and neurite
outgrowth was imaged at 48 and 76 h, using MetaXPress.
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Beutler et al., 2014; Li et al., 2015b; Boora et al., 2015; Reyes-Gibby
et al., 2015) was signiﬁcantly (FDR b 0.2) affected by batch.3.3. Modiﬁed cytosine proﬁling of different batches of neurons
We then analyzed cytosine modiﬁcation levels using the Illumina
450K arrays for 4 neuron batches at the same 4 different plating time
points. PCA plot of the β-value matrix was obtained from the 450K
array data (Fig. 2B). gPCA test indicated that no signiﬁcant batch effect
separating the batches (δ = 0.44; P-value = 0.50) was detected
(Fig. 2B). Similar to the RNA-Seq data, 89.28% of the variance was ex-
plained by temporal changes in the 450K array data, while 56.4% of
the total variance could be explained by batch. These results suggested
that both gene expression and cytosine modiﬁcation measurements
were consistent across different batches but changed as neurites were
formed in culture, as expected.Table 2
Four independently differentiated neurons and the experiments performed with each
batch.
Batch #
Lot #
Plating
time (h)
Number of replicates
RNA-Seq 450K assay Sensitivity assay
1
1369525
4 2 2 3
28 2 3 –
76 2 3 –
2
1366825
4 2 3 3
28 2 3 –
76 2 3 –
3
1366431
0 2 3 –
4 2 4 3
28 2 4 –
76 – 4 –
4
1362632
0 2 3 –3.4. Phenotypic measures of chemotherapeutic sensitivity of different
batches of neurons
We alsomeasured neuronal phenotype (i.e., pharmacologic response
to chemotherapy), in three out of four batches of the neurons. Human
neurons reprogrammed from ﬁbroblasts have been used to study che-
motherapeutics that cause CIPN (Wainger et al., 2015; Wheeler et al.,
2015) and genes associated with clinical CIPN (Wheeler et al., 2015;
Leandro-Garcia et al., 2012; Diouf et al., 2015; Komatsu et al., 2015).
We identiﬁed no signiﬁcant differences between batches in sensitivities
to paclitaxel, vincristine and cisplatin as determined by total neurite out-
growth (Fig. 3A), number of processes (Fig. 3B) and branches (Fig. 3C)
and as illustrated morphologically for 0, 0.1 and 10 μM paclitaxel
(Fig. 3D), vincristine (Fig. 3E) and cisplatin (Fig. 3F).3.5. Enrichment of highly expressed neuropathy related genes in the neuron
model
Tissue-speciﬁc models are essential in understanding mechanisms
of disease onset and drug induced toxicity, however expression of
genes critical to the disease is necessary for the model to be useful.
We therefore sought to investigate the degree to which established
neuropathy associated genes were enriched in this neuronal cell
model. Fig. 4 illustrates the median gene expression levels of
neuropathy-associated genes at each time point. In the gene expression
data, we found that at each time point (0, 4, 28 and 76 h), hereditary
neuropathy related genes fromOMIMwere highly expressed compared
with background distribution across the human genome (empirical
P-value b 0.001) (Fig. 4A). In addition, a few known CIPN related
genes from previous publications also showed a trend of enrichment
of highly expressed genes relative to the background (Fig. 4B,
Table 1). To determine if this enrichment was speciﬁc to neuropathic
disease but not other diseases, we evaluated diabetes-associated
genes as a negative control and found no enrichment (Fig. 4C). These re-
sults overall suggest that this is a relevant neuronal model to study the
pathophysiology of neuropathy.
Fig. 2.Analyzing batch effect using RNA-Seq and Illumina 450K array. Four independent batches of neurons denoted by shapes (square: lot # 1366825, triangle: lot # 1366431, circle: lot #
1369525 anddiamond: lot # 1362632)were collected at different time points (0, 4, 28, 76 h) denotedby color. Lot # 1362632 had pellets collected only at time point 0. A) A PCA plot of the
log-transformed RNA-Seq data in FPKM(fragments per kilobase of transcript permillionmapped reads); B) a PCA plot of theβ-values from the Illumina 450K array. PC1: the ﬁrst principal
component; PC2: the second principal component.
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We evaluated inter-batch variability of differentiated neurons in
order to provide insight into variability associated with manufacturing
neurons from iPSCs (i.e., the differentiation process). It is important to
consider the magnitude of noise introduced by processing the cells rel-
ative to biological signal. High quality and stable iPSC-derived neurons
depend on the robustness of the manufacturing protocol for both the
iPSC-differentiated cells and the production of the iPSCs themselves
(Ohnuki et al., 2014). Such standards of quality are most practically
achieved by large core facilities and commercial manufacturers.
In our study, four independent productions of iCell Neurons were ob-
tained from CDI; each production represents an independent differentia-
tion from the same iPSC clone. We found through RNA-Seq analysis that
gene expression variation due to different batcheswas not amajor source
of variance compared to changes over time. Modiﬁed cytosine changes
also showed no signiﬁcant variation across batches as compared to time
dependent changes suggesting that the differentiation process results in
minimal intra-individual variation. The lack of signiﬁcant variation of neu-
ronal sensitivity to neurotoxic chemotherapeutics for 3 separate batches
provided further conﬁdence that inter-batch variation is minimal. We
next investigatedwhether the iPSC-derived neuronalmodel system is ad-
equately enriched for the genes essential in identifying mechanisms of
neuronal diseases and drug-induced neurotoxicities. Indeed, we found
that the neurons were enriched for highly expressed genes implicated
in hereditary neuropathy and showed an enrichment trend for a few
genes known to be associated with chemotherapeutic-induced neuropa-
thy. The lack of signiﬁcance of CIPN related genes may be because of our
limited knowledge of genes contributing to CIPN. The speciﬁcity of our
model was further conﬁrmed when we found that our model was not
enriched for genes implicated in other disease types, such as diabetes.
An advantage of the creation of patient-derived iPSCs is that they re-
tain the genetic “makeup” of the donor allowing for in vitro studies of
neurons from patients with speciﬁc diseases that harbor the complex
genetic background associated with the disorder (Ohnuki et al., 2014).
The successful generation of iPSCs from patients' speciﬁc somatic cells,and differentiation to cortical neurons, have offered cell resources for
disease modeling and potential cell transplantation therapy (Corti
et al., 2015). This revolutionary technology has already helped to ad-
vance our understanding of many diseases and inform mechanistically
rationalized therapies, which are desperately needed in this arena
(Mullard, 2015; Wiethoff et al., 2015).
Charcot–Marie tooth (CMT) is one of the most common inherited
neurological disorders, characterized by weakness of the foot and
lower leg muscle (Newman et al., 2007) and has no effective treatment.
Therefore, human iPSCs can lead to the identiﬁcation and optimization
of potential drugs and thus move forward new pharmacological thera-
pies for a wide range of neurodegenerative and neurodevelopmental
conditions (Corti et al., 2015). Critical to this ﬁeld is the consistent
manufacturing of differentiated neurons from iPSCs. Therefore, our
evaluation of gene expression and modiﬁed cytosines at baseline, and
changes over time following plating, will provide a framework for stud-
ies of these neurons. Furthermore, we show batch-to-batch consistency
of iPSC-derived neurons in gene expression, modiﬁed cytosines and re-
sponse to neurotoxic chemotherapeutics.
Creating a genetically diverse set of differentiated cells for the
purposes of phenotype-genotype studies would have great value
in pharmacogenomics, a ﬁeld that has relied primarily on EBV-
transformed lymphoblastoid cell lines (Moen et al., 2012; Wheeler and
Dolan, 2012;Welsh et al., 2009). Tissue speciﬁc cells will provide the ap-
propriate model for functionally validating ﬁndings from large clinical
genome wide association studies. Therefore, the development of
human iPSC-derived neurons as a model system could have important
implications for studies of neurotoxicity and developing new drugs to
prevent or treat heritable neuropathy and/or CIPN, one of themost com-
mon and sometimes permanent side effects of chemotherapy (Alberti
et al., 2014; Cavaletti et al., 2013).
5. Conclusion
Our results indicate that batch-to-batch variation in gene expres-
sion, modiﬁed cytosines and drug sensitivity was not a major source
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Fig. 3. Effect of chemotherapeutic agents on neuronal outgrowth. Three batches of iCell Neurons out of the four batches were treated with increasing concentrations of paclitaxel (PTX,
purple), vincristine (VCR, blue) or cisplatin (CDDP, orange) for 72 h, and analyzed with the MetaXPress software for (A) relative total outgrowth; (B) relative number of processes;
and (C) relative number of branches. The three batches are represented as shaded differences in color for each drug response curve (lightest shade: lot # 1369525; medium shade: lot
# 1366825 and darkest shade: lot # 1366431). Representative 10× images of 3 batches iCell Neurons treated with different concentrations of vehicle (DMSO or PBS), 0.1 μM or 10 μM
of (D) PTX, (E) VCR and (F) CDDP at 72 h using ImageXpress Micro.
146 G. Morrison et al. / Stem Cell Research 16 (2016) 140–148
Fig. 4. Assessing enrichment of neuropathy associated genes in neuronal model. Median gene expression levels measured as log FPKM (X-axis) of: A) hereditary neuropathy-; B) CIPN-;
and C) diabetes-associated genes at each time point are indicated by red asterisks. The histograms show the null distributions (frequencies on the Y-axis) generated by random samplings
of the same number of genes across the human genome. Empirical P-values are indicated for each situation. CIPN: chemotherapy-induced peripheral neuropathy; FPKM: fragments per
kilobase of transcript per million mapped reads.
147G. Morrison et al. / Stem Cell Research 16 (2016) 140–148of variances compared to the time effect. The enrichment of neuropathy
associated genes in the neurons in contrast to other diseases such as di-
abetes, gives us a clinically relevant cell-based model that will allow us
to understand the mechanisms of neurological disease and drug in-
duced neurotoxicities. This model also provides a ﬂexible platform to
test potential neurotoxic and/or neuroprotectant drugs.
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